ReviewImmunotherapy2011
More than just a T-box: the role of T-bet as a possible biomarker and therapeutic target in autoimmune diseases.
Review in Immunotherapy, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- Downregulation of T-bet/GATA-3 ratio induced by IL-11 treatment is responsible for Th1/Th2 balance restoration in human immune thrombocytopenic purpura (ITP).Journal of thrombosis and thrombolysis · 2014Trial
- PROTACs coupled with oligonucleotides to tackle the undruggable.Bioanalysis · 2025Review
- Epstein-Barr virus: the mastermind of immune chaos.Frontiers in immunology · 2024Review
- Mechanisms and biotechnological applications of transcription factors.Synthetic and systems biotechnology · 2023Review
- Neuroinflammation: Extinguishing a blaze of T cells.Immunological reviews · 2022Review
- Advances in targeting 'undruggable' transcription factors with small molecules.Nature reviews. Drug discovery · 2021Review
- A pathogenic and clonally expanded B cell transcriptome in active multiple sclerosis.Proceedings of the National Academy of Sciences of the United States of America · 2020Article
- Potential T Cell-Intrinsic Regulatory Roles for IRF5 via Cytokine Modulation in T Helper Subset Differentiation and Function.Frontiers in immunology · 2020Review
- Increased expression of microRNAs, miR-20a and miR-326 in PBMCs of patients with type 1 diabetes.Molecular biology reports · 2018Article
- The protective role of TBX21-1514T>C polymorphism in susceptibility to multiple sclerosis.Iranian journal of neurology · 2018Article
- T cell subsets and their signature cytokines in autoimmune and inflammatory diseases.Cytokine · 2015Review
- Genetic variation of TBX21 gene increases risk of asthma and its severity in Indian children.Journal of human genetics · 2014Article
- Sarcoidosis: Immunopathogenesis and Immunological Markers.International journal of chronic diseases · 2013Review
- Morphine, but not ketamine, decreases the ratio of Th1/Th2 in CD4-positive cells through T-bet and GATA3.Inflammation · 2012Article
- Tipifarnib-mediated suppression of T-bet-dependent signaling pathways.Cancer immunology, immunotherapy : CII · 2012Article
- Ginger supplementation in children with oligoarticular juvenile idiopathic arthritis: A triple-blind randomized clinical trial.Avicenna journal of phytomedicineArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
T-bet was initially described as a T-box transcription factor with an essential role in orchestrating Th1 cell differentiation. Subsequently, it was determined that T-bet controls the expression of numerous cytokines and their receptors, adhesion molecules and chemokine receptors, and therefore determines the differentiation and development status of many types of immune cells. The critical role of T-bet in autoimmune diseases, particularly multiple sclerosis and its animal model experimental autoimmune encephalomyelitis, implicates it as a potential biomarker for pathogenic T cells as well as a therapeutic drug target.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.